-
EP3710480
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3710480
| EP3710480 - SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1 [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 21.08.2020 Database last updated on 28.06.2024 | |
| Former | The international publication has been made Status updated on 28.05.2019 | Most recent event Tooltip | 20.11.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Nanjing Legend Biotech Co., Ltd. No.6 Building of Nanjing Life Science Town No. 568 Longmian Avenue Jiangning District Nanjing, Jiangsu 211100 / CN | [2020/39] | Inventor(s) | 01 /
ZHANG, Yafeng 599 Lize Road Building 35 Room 302 Moling Street Jiangning District Nanjing Jiangsu 211100 / CN | 02 /
WU, Shu 28 Chengxu Road Huayu Court Building 3 Room 501 Moling Street Jiangning District Nanjing Jiangsu 211100 / CN | 03 /
YANG, Shuai 228 Tianyuan East Road Lander East County Yingxiayuan Building 10 Room 203, Jiangning District, Nanjing Jiangsu 211100 / CN | 04 /
CHOU, Chuan-Chu 909 Prospect Street Westfield New Jersey 07090 / US | [2020/39] | Representative(s) | Synergy IP Group AG Leonhardsgraben 52 Postfach 4001 Basel / CH | [N/P] |
| Former [2020/39] | Pharma Patents International AG Leonhardsgraben 52 4051 Basel / CH | Application number, filing date | 18877388.1 | 13.11.2018 | [2020/39] | WO2018CN115213 | Priority number, date | WO2017CN111712 | 17.11.2017 Original published format: PCT/CN2017/111712 | [2020/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019096121 | Date: | 23.05.2019 | Language: | EN | [2019/21] | Type: | A1 Application with search report | No.: | EP3710480 | Date: | 23.09.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.05.2019 takes the place of the publication of the European patent application. | [2020/39] | Search report(s) | International search report - published on: | CN | 23.05.2019 | (Supplementary) European search report - dispatched on: | EP | 11.11.2021 | Classification | IPC: | C07K16/28, A61K39/395, A61P35/00, A61P31/00, C12N15/13, C12N15/85, C12N5/10 | [2020/39] | CPC: |
C07K16/2827 (EP,IL,KR,US);
A61K39/3955 (US);
A61K45/06 (US);
A61P31/00 (EP,IL,KR);
A61P35/00 (EP,IL,KR,US);
A61K2039/505 (EP,IL,KR,US);
C07K2317/21 (US);
C07K2317/22 (EP,IL,KR,US);
C07K2317/24 (EP,IL,KR,US);
C07K2317/31 (US);
C07K2317/52 (EP,IL,KR);
C07K2317/569 (EP,IL,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/39] | Title | German: | EINZELDOMÄNENANTIKÖRPER UND VARIANTEN DAVON GEGEN PD-L1 | [2020/39] | English: | SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1 | [2020/39] | French: | ANTICORPS À DOMAINE UNIQUE ET DES VARIANTS DE CELUI-CI DIRIGÉS CONTRE PD-L1 | [2020/39] | Entry into regional phase | 12.06.2020 | National basic fee paid | 12.06.2020 | Search fee paid | 12.06.2020 | Designation fee(s) paid | 12.06.2020 | Examination fee paid | Examination procedure | 12.06.2020 | Examination requested [2020/39] | 30.05.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 12.06.2020 | Renewal fee patent year 03 | 28.01.2022 | Renewal fee patent year 04 | 13.10.2022 | Renewal fee patent year 05 | 20.11.2023 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 30.11.2021 | 04 M06 Fee paid on 28.01.2022 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2017020801 (SUZHOU ALPHAMAB CO LTD [CN]) [I] 1-15 * See examples, claims *; | [I] - FEI ZHANG ET AL, "Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade", CELL DISCOVERY, (20170307), vol. 3, doi:10.1038/celldisc.2017.4, page 17004, XP055490308 [I] 1-15 * the whole document * DOI: http://dx.doi.org/10.1038/celldisc.2017.4 |